# Curigin co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/curigin-co

- Industry: Biotechnology
- Headquarters: Seoul, South Korea
- Website: www.curigin.com/
- Total disclosed funding: $15M
- Latest round: Series A (Apr 30, 2021)
- Investors on record: 8

## About

Based in South Korea, Curigin co., Ltd. specializes in creating and commercializing innovative biopharmaceutical products to address significant medical needs across various therapeutic areas.Founded in 2016 and headquartered in Seoul, South Korea, Curigin co., Ltd. focuses on developing biopharmaceuticals. The company has engaged in three significant deals as of April 30, 2021, when they raised KRW 11.5 billion in a SERIES A funding round led by investors such as LB Investment and Timefolio Asset Management. The total amount raised by the company to date stands at KRW 11.5 billion, with a current valuation of KRW 66.5 billion.??? specializes in the development and commercialization of innovative biopharmaceutical products aimed at addressing unmet medical needs. The company’s core offerings include advanced therapeutics for various diseases, leveraging proprietary technology platforms designed for enhanced efficacy and safety. These products are tailored to treat specific conditions and have been developed through rigorous clinical trials to ensure they meet regulatory standards. Their primary customer base consists of healthcare providers, including hospitals and clinics, as well as pharmaceutical distributors who facilitate access to end-users such as patients affected by chronic and acute medical conditions. ???'s products are marketed in key geographical regions, including North America, Europe, and parts of Asia, where there is a demand for therapeutic solutions.??? generates revenue primarily through direct sales of its biopharmaceutical products to healthcare institutions and through partnerships with distributors. The company operates a business-to-business (B2B) model, where products are sold to hospitals and clinics that then prescribe them to patients. Revenue is structured around transactional agreements that may include bulk purchase discounts for large orders or subscription models for ongoing supply agreements. One of the flagship products, known for its unique formulation, is offered at a competitive price point to ensure accessibility for healthcare providers. These structured transactions foster ongoing relationships with clients, facilitating consistent revenue streams as the company expands its product offerings and market presence.In April 2021, Curigin co., Ltd. raised KRW 11.5 billion in a SERIES A funding round, part of a larger KRW 17 billion financing, to support its growth initiatives. The funds will ensure GMP-compliant manufacturing in preparation for its flagship products' clinical trials. Curigin plans to develop and launch several new products targeting unmet medical needs, with anticipated releases scheduled over the upcoming years. The company is also strategizing expansion into new markets across Europe and Asia by 2024, aiming to enhance its global footprint.

## Funding rounds

- Series A, Apr 30, 2021, $10M — LB Investment, Timefolio Asset Management, Company K Partners, Wooshin Venture Capital, Hana Securities
- Series A, May 31, 2019, $4.7M — Korea Investment Partners, DSC Investment, Schmidt

## Investors

- Korea Investment Partners (https://capitalatlas.ai/funds/korea-investment-partners) — Series A
- DSC Investment (https://capitalatlas.ai/funds/dsc-investment) — Series A
- Schmidt (https://capitalatlas.ai/funds/schmidt) — Series A
- LB Investment (https://capitalatlas.ai/funds/lb-investment) — Series A
- Timefolio Asset Management — Series A
- Company K Partners (https://capitalatlas.ai/funds/company-k-partners) — Series A
- Wooshin Venture Capital (https://capitalatlas.ai/funds/wooshin-venture-capital) — Series A
- Hana Securities (https://capitalatlas.ai/funds/hana-securities) — Series A